Detalles de la búsqueda
1.
Serum soluble mediators as prognostic biomarkers for morbidity, disease outcome, and late-relapsing hepatitis in yellow fever patients.
Clin Immunol
; 251: 109321, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37019421
2.
Safety and immunogenicity of 17DD attenuated yellow fever vaccine in howler monkeys (Alouatta spp.).
J Med Primatol
; 50(1): 36-45, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33219623
3.
Validation of a yellow fever vaccine model using data from primary vaccination in children and adults, re-vaccination and dose-response in adults and studies with immunocompromised individuals.
BMC Bioinformatics
; 21(Suppl 17): 551, 2020 Dec 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-33308151
4.
Impact of HIV-Related Immune Impairment of Yellow Fever Vaccine Immunogenicity in People Living with HIV-ANRS 12403.
Vaccines (Basel)
; 12(6)2024 May 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-38932307
5.
Duration of post-vaccination immunity to yellow fever in volunteers ten years after a dose-response study - A complementary study.
Vaccine
; 2024 Jun 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-38926068
6.
Plaque Reduction Neutralization Test (PRNT) Accuracy in Evaluating Humoral Immune Response to SARS-CoV-2.
Diseases
; 12(1)2024 Jan 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-38248380
7.
Immune response induced by standard and fractional doses of 17DD yellow fever vaccine.
NPJ Vaccines
; 9(1): 54, 2024 Mar 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38459059
8.
Comprehensive landscape of neutralizing antibody and cell-mediated response elicited by the 1/5 fractional dose of 17DD-YF primary vaccination in adults.
Sci Rep
; 14(1): 7709, 2024 04 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38565882
9.
Standardization, validation, and comparative evaluation of a faster and high-performance test for quantification of yellow fever neutralizing antibodies.
J Immunol Methods
; 522: 113568, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37748728
10.
Case report: Regression of Glioblastoma after flavivirus infection.
Front Med (Lausanne)
; 10: 1192070, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37324152
11.
Differential gene expression of cytokines, receptors, and miRNAs in individuals living with HIV-1 and vaccinated against yellow fever.
Mol Immunol
; 164: 58-65, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37952362
12.
Inactivated and Immunogenic SARS-CoV-2 for Safe Use in Immunoassays and as an Immunization Control for Non-Clinical Trials.
Viruses
; 15(7)2023 06 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-37515173
13.
Timeline kinetics of protective immunity to SARS-CoV-2 upon primary vaccination and humoral response to variants after booster dose.
Vaccine
; 41(44): 6514-6528, 2023 Oct 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-37661534
14.
Neotropical Sylvatic Mosquitoes and Aedes aegypti Are Not Competent to Transmit 17DD Attenuated Yellow Fever Virus from Vaccinated Viremic New World Non-Human Primates.
Viruses
; 14(10)2022 10 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36298786
15.
Effectiveness, safety, and immunogenicity of half dose ChAdOx1 nCoV-19 COVID-19 Vaccine: Viana project.
Front Immunol
; 13: 966416, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36105814
16.
Molecular and Cellular Biomarkers of COVID-19 Prognosis: Protocol for the Prospective Cohort TARGET Study.
JMIR Res Protoc
; 10(3): e24211, 2021 Mar 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33661132
17.
Serum biomarker profile orchestrating the seroconversion status of patients with autoimmune diseases upon planned primary 17DD Yellow fever vaccination.
Sci Rep
; 11(1): 10431, 2021 05 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-34001945
18.
Detection of Yellow Fever Virus by Quantitative Real-Time PCR (qPCR).
Methods Mol Biol
; 2065: 65-77, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-31578688
19.
Planned Yellow Fever Primary Vaccination Is Safe and Immunogenic in Patients With Autoimmune Diseases: A Prospective Non-interventional Study.
Front Immunol
; 11: 1382, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32765496
20.
Impact of synthetic and biological immunomodulatory therapy on the duration of 17DD yellow fever vaccine-induced immunity in rheumatoid arthritis.
Arthritis Res Ther
; 21(1): 75, 2019 03 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-30871593